PAION plans news composition of executive management

Dr. Mariola Söhngen will leave management board

09-Jul-2015 - PAION AG announced that Dr. Mariola Söhngen, Chief Medical Officer (CMO) and co-founder of the Company, has informed the Chairman of the Supervisory Board that she wants to leave the Management Board of the Company prior to the end of her current appointment until 31 December 2016 to pursue a new ...

PAION AG: Management Board Change

26-Apr-2011 - The biopharmaceutical company PAION AG announced that Dr Gavin Kilpatrick has stepped down from his position as a member of the Management Board and will be leaving the company on 30 April 2011. In his role as Chief Scientific Officer, Dr Kilpatrick was responsible for production, pre-clinical ...

PAION AG: Phase Ib and IIa Studies of the Anesthetic/Sedative CNS 7056 on Track

16-Jul-2009 - The biopharmaceutical company PAION AG announces that the respective Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that the Company should proceed as planned with their Phase IIa study as well as Phase Ib of CNS 7065, a new short-acting intravenous ...

PAION AG: Court sanctions Scheme of Arrangement for acquisition of CeNeS

24-Jun-2008 - The management board of PAION AG and the board of directors of CeNeS Pharmaceuticals plc announced that at the Court Hearing, the Court of Session in Edinburgh, Scotland, sanctioned the Scheme of Arrangement, which describes the terms and conditions of the proposed acquisition, under part 26 of ...

PAION agreement with Lundbeck comes into force, securing future Desmoteplase development and EUR 8 million upfront-payment

30-Jan-2008 - PAION AG announced that the expanded licensing agreement with H. Lundbeck A/S regarding the compound Desmoteplase has now come into force without any condition after Lundbeck's positive completion of its IP due diligence. As a result, PAION will receive an non-refundable upfront payment amounting ...

PAION sees continued development rationale for Desmoteplase based on findings from Phase III analysis

Reasons identified for high placebo response rate in Phase III stroke study DIAS-2

22-Oct-2007 - PAION AG reported that it has reviewed findings from the analysis of the DIAS-2 (Desmoteplase in Acute ischemic Stroke) study results. In contrast to previous Phase II studies, the DIAS-2 study did not meet its primary efficacy endpoint due to a lack of improvement in the Desmoteplase groups over ...

PAION reduces number of employees

27-Jun-2007 - PAION AG announced that the management board and the supervisory board agreed on an action plan to significantly reduce external and internal costs. The decision was taken based on the unexpected results of the Phase III study DIAS-2 which was conducted with the drug candidate Desmoteplase. As ...

Paion initiates programme of next generation plasminogen activators

28-Mar-2006 - PAION AG announced the initiation of a new plasminogen activator programme, which is intended to serve as a long-term life cycle management tool for Desmoteplase and a mid term option for indications not within the current profile and development programme of Desmoteplase. PAION announced that ...